EssilorLuxottica Acquires Cellview Imaging to Strengthen Retinal Diagnostic Capabilities
EssilorLuxottica has announced the acquisition of Cellview Imaging, a Toronto-based med-tech start-up specializing in retinal imaging diagnostics. The financial terms of the transaction were not disclosed. This acquisition marks a strategic expansion in ophthalmic technology, reinforcing EssilorLuxottica’s commitment to advancing vision health through cutting-edge diagnostic solutions.
Cellview’s Innovative Retinal Imaging Technology
Cellview Imaging designs and manufactures diagnostic imaging instruments, offering advanced ultra-widefield retinal imaging that captures significantly larger retinal images compared to most existing technologies. Currently distributed in North America, Cellview’s solutions are FDA- and CE Mark-approved and cater to a broad market base, including:
• Retail-based eye care practices
• Ophthalmology clinics
EssilorLuxottica plans to expand Cellview’s distribution globally, beginning with Europe.
Enhancing Vision Health Through Cutting-Edge Diagnostics
The integration of Cellview aligns with EssilorLuxottica’s med-tech strategy, bringing pioneering expertise in R&D and world-class imaging solutions to its portfolio.
Francesco Milleri, Chairman and CEO, and Paul du Saillant, Deputy CEO of EssilorLuxottica, highlighted the strategic significance of this acquisition:
"We are happy to welcome Cellview’s team to EssilorLuxottica and to work together to accelerate our strategy in vision health. By integrating another pioneering company with strong expertise in R&D and world-class imaging solutions, we will provide a comprehensive portfolio of innovative technologies to the ophthalmic care community to better address the growing need for vision health and the early diagnosis of retinal pathologies."
They further emphasized that while EssilorLuxottica’s products and services remain accessible to all industry players—a core aspect of its open business model—the company continues to elevate market standards in the med-tech space.
Advancing the Future of Retinal Disease Detection
With this acquisition, EssilorLuxottica strengthens its role in vision diagnostics, expanding its capabilities in early retinal disease detection and reinforcing its commitment to innovation in eye care. As the demand for advanced diagnostic solutions grows, this strategic move is expected to enhance accessibility, precision, and efficiency in retinal imaging worldwide.
